28 August 2014 in BMC Cancer
Patients with Ewing sarcoma family of tumors (ESFT) who are resistant even to salvage chemotherapy, have dismal prognoses and few therapeutic options. Because the docetaxel/irinotecan (DI) combination has not been previously evaluated in ESFT, we prospectively evaluated its use in patients with recurrent or refractory ESFT. Patients aged <30 years with ESFT, who failed ≥ third-line therapy, were eligible. They received docetaxel 100 mg/m2 intravenously on day 1, and irinotecan 80 mg/m2 on days 1 and 8, of a 21-day cycle up to 15 cycles or until disease progressed. The primary objective was objective response rate (ORR); secondary objectives were progression-free survival (PFS) and safety. We enrolled nine patients (median age: 13 years); four were male. Two patients had recurrent disease and seven had progressive disease. This group had undergone a median of four prior chemotherapy regimens (range: 3-6), and received a total of 51 DI cycles (median: three cycles/per person; range: 1-15 cycles). The nine patients showed one complete response (CR), two partial responses (PRs), one stable disease, and five progressive diseases, for an ORR (CR + PR) of 3/9 (33.3%). Two patients with PR achieved CR with subsequent surgery. Overall median PFS was 2.2 months (range: 0.5-16.9 months). All nine patients had grade 4 neutropenia (100%); grade 3 diarrhea or grade 2/3 neuropathy each occurred in two patients (22%). All toxicities were manageable without serious morbidities or treatment-related mortality. The DI combination may be effective and tolerable for patients with heavily pre-treated ESFT. NCT01380275 . Registered June 21, 2011.
3 November 2025 in Cancer Immunology, Immunotherapy
Background: Thyroid cancer is the most common endocrine malignancy, with an increasing incidence, particularly driven by differentiated thyroid cancers (DTC), including papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). Although DTC generally have excellent prognosis, dedifferentiated forms such as poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) exhibit aggressive progression and poor outcomes. Understanding the tumor microenvironment (TME) is crucial for developing novel therapeutic strategies. Methods: We performed spatial transcriptomics (ST) on formalin-fixed paraffin-embedded (FFPE) tumor tissues from 12 patients with PTC, FTC, PDTC, or ATC using the Visium CytAssist platform. Cell type composition was inferred using the CellDART algorithm, and pathway activity was assessed via PROGENy and REACTOME analyses. Immunohistochemical (IHC) assays were conducted to validate key TME components. Results: ST analysis revealed significant shifts in cell composition associated with thyroid cancer dedifferentiation. Specifically, there was an increase in myeloid cells and cancer-associated fibroblasts (CAFs), accompanied by a reduction in natural killer (NK) cells and endothelial cells. Intratumoral heterogeneity in the Thyroid Differentiation Score (TDS) showed a strong spatial correlation with myeloid cell density, and among myeloid subtypes, the MDSC score was negatively correlated with TDS. Pathway activity analysis further identified upregulation of the JAK-STAT and VEGF signaling pathways in dedifferentiated tumors, both of which were closely associated with increased myeloid cell infiltration. IHC validation confirmed the differential expression patterns of representative immune and stromal markers across subtypes. Conclusions: These findings suggest that dedifferentiation in thyroid cancer is associated with an immunosuppressive TME that promotes tumor progression. Therapeutic strategies targeting JAK-STAT and VEGF pathways, or enhancing NK cell activity, may hold promises for aggressive thyroid cancers. Further studies with larger cohorts are necessary to validate these findings and develop targeted therapies for aggressive thyroid cancers.
1 December 2020 in European Journal of Cancer